Sinopharm: The clinical trial application for the innovative injectable drug SAL012 has been accepted.

Xintai announced that the company and its wholly-owned subsidiary received the acceptance notice from the National Medical Products Administration. The clinical trial application for the independently developed Class 1 new drug, injectable SAL012, for the treatment of advanced solid tumors has been accepted, with acceptance number CXSL2600858. If no negative or questioning feedback is received within 60 days from the date of acceptance, clinical trials may proceed according to the submitted plan.